U.S. Markets open in 1 hr 20 mins

Does BioTelemetry, Inc. (NASDAQ:BEAT) Have A High Beta?

Simply Wall St

If you own shares in BioTelemetry, Inc. (NASDAQ:BEAT) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market.

Some stocks see their prices move in concert with the market. Others tend towards stronger, gentler or unrelated price movements. Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). However, Warren Buffett said 'volatility is far from synonymous with risk' in his 2014 letter to investors. So, while useful, beta is not the only metric to consider. To use beta as an investor, you must first understand that the overall market has a beta of one. A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Check out our latest analysis for BioTelemetry

What does BEAT's beta value mean to investors?

Given that it has a beta of 1.32, we can surmise that the BioTelemetry share price has been fairly sensitive to market volatility (over the last 5 years). Based on this history, investors should be aware that BioTelemetry are likely to rise strongly in times of greed, but sell off in times of fear. Beta is worth considering, but it's also important to consider whether BioTelemetry is growing earnings and revenue. You can take a look for yourself, below.

NasdaqGS:BEAT Income Statement, May 17th 2019

How does BEAT's size impact its beta?

BioTelemetry is a small company, but not tiny and little known. It has a market capitalisation of US$1.7b, which means it would be on the radar of intstitutional investors. It's not particularly surprising that it has a higher beta than the overall market. That's because it takes less money to influence the share price of a smaller company, than a bigger company.

What this means for you:

Since BioTelemetry has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment. For example, it might be a high growth stock or have a lot of operating leverage in its business model. In order to fully understand whether BEAT is a good investment for you, we also need to consider important company-specific fundamentals such as BioTelemetry’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Future Outlook: What are well-informed industry analysts predicting for BEAT’s future growth? Take a look at our free research report of analyst consensus for BEAT’s outlook.
  2. Past Track Record: Has BEAT been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of BEAT's historicals for more clarity.
  3. Other Interesting Stocks: It's worth checking to see how BEAT measures up against other companies on valuation. You could start with this free list of prospective options.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.